|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TARS2 |
Gene summary for TARS2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TARS2 | Gene ID | 80222 |
| Gene name | threonyl-tRNA synthetase 2, mitochondrial | |
| Gene Alias | COXPD21 | |
| Cytomap | 1q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000959 | UniProtAcc | U3KQG0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80222 | TARS2 | LZE7T | Human | Esophagus | ESCC | 3.98e-06 | 2.67e-01 | 0.0667 |
| 80222 | TARS2 | LZE24T | Human | Esophagus | ESCC | 3.74e-07 | 1.82e-01 | 0.0596 |
| 80222 | TARS2 | P1T-E | Human | Esophagus | ESCC | 1.09e-04 | 2.06e-01 | 0.0875 |
| 80222 | TARS2 | P2T-E | Human | Esophagus | ESCC | 3.56e-21 | 3.09e-01 | 0.1177 |
| 80222 | TARS2 | P4T-E | Human | Esophagus | ESCC | 1.49e-09 | 2.00e-01 | 0.1323 |
| 80222 | TARS2 | P5T-E | Human | Esophagus | ESCC | 2.74e-13 | 2.48e-01 | 0.1327 |
| 80222 | TARS2 | P8T-E | Human | Esophagus | ESCC | 2.09e-08 | 1.45e-01 | 0.0889 |
| 80222 | TARS2 | P9T-E | Human | Esophagus | ESCC | 6.74e-06 | 1.53e-01 | 0.1131 |
| 80222 | TARS2 | P10T-E | Human | Esophagus | ESCC | 4.24e-09 | 2.10e-01 | 0.116 |
| 80222 | TARS2 | P11T-E | Human | Esophagus | ESCC | 6.08e-06 | 2.78e-01 | 0.1426 |
| 80222 | TARS2 | P12T-E | Human | Esophagus | ESCC | 9.27e-09 | 1.65e-01 | 0.1122 |
| 80222 | TARS2 | P15T-E | Human | Esophagus | ESCC | 1.16e-16 | 3.35e-01 | 0.1149 |
| 80222 | TARS2 | P16T-E | Human | Esophagus | ESCC | 6.96e-14 | 2.55e-01 | 0.1153 |
| 80222 | TARS2 | P17T-E | Human | Esophagus | ESCC | 1.49e-02 | 2.22e-01 | 0.1278 |
| 80222 | TARS2 | P19T-E | Human | Esophagus | ESCC | 6.53e-04 | 3.59e-01 | 0.1662 |
| 80222 | TARS2 | P20T-E | Human | Esophagus | ESCC | 3.20e-07 | 1.49e-01 | 0.1124 |
| 80222 | TARS2 | P21T-E | Human | Esophagus | ESCC | 3.23e-14 | 2.92e-01 | 0.1617 |
| 80222 | TARS2 | P22T-E | Human | Esophagus | ESCC | 2.98e-12 | 2.41e-01 | 0.1236 |
| 80222 | TARS2 | P23T-E | Human | Esophagus | ESCC | 2.33e-14 | 3.01e-01 | 0.108 |
| 80222 | TARS2 | P24T-E | Human | Esophagus | ESCC | 8.08e-19 | 4.75e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00009592 | Esophagus | ESCC | mitochondrial RNA metabolic process | 39/8552 | 49/18723 | 1.20e-06 | 1.49e-05 | 39 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:01400531 | Liver | HCC | mitochondrial gene expression | 82/7958 | 108/18723 | 1.49e-12 | 7.20e-11 | 82 |
| GO:00325431 | Liver | HCC | mitochondrial translation | 62/7958 | 76/18723 | 2.95e-12 | 1.34e-10 | 62 |
| GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
| GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
| GO:0000959 | Liver | HCC | mitochondrial RNA metabolic process | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:01400533 | Oral cavity | OSCC | mitochondrial gene expression | 78/7305 | 108/18723 | 2.37e-12 | 9.86e-11 | 78 |
| GO:00325434 | Oral cavity | OSCC | mitochondrial translation | 59/7305 | 76/18723 | 7.21e-12 | 2.70e-10 | 59 |
| GO:00063991 | Oral cavity | OSCC | tRNA metabolic process | 101/7305 | 179/18723 | 1.65e-06 | 2.15e-05 | 101 |
| GO:00009591 | Oral cavity | OSCC | mitochondrial RNA metabolic process | 29/7305 | 49/18723 | 3.33e-03 | 1.42e-02 | 29 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TARS2 | SNV | Missense_Mutation | c.1039G>T | p.Gly347Cys | p.G347C | Q9BW92 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| TARS2 | SNV | Missense_Mutation | novel | c.839N>T | p.Ser280Phe | p.S280F | Q9BW92 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
| TARS2 | SNV | Missense_Mutation | novel | c.2083N>A | p.Asp695Asn | p.D695N | Q9BW92 | protein_coding | tolerated(0.23) | benign(0.175) | TCGA-A2-A4RX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TARS2 | SNV | Missense_Mutation | c.1383C>G | p.Ile461Met | p.I461M | Q9BW92 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| TARS2 | SNV | Missense_Mutation | c.1180N>C | p.Ser394Pro | p.S394P | Q9BW92 | protein_coding | tolerated(0.5) | benign(0.001) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| TARS2 | SNV | Missense_Mutation | c.1621N>C | p.Asp541His | p.D541H | Q9BW92 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| TARS2 | SNV | Missense_Mutation | novel | c.1946N>G | p.Ser649Cys | p.S649C | Q9BW92 | protein_coding | tolerated(0.05) | benign(0.006) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
| TARS2 | SNV | Missense_Mutation | rs776209620 | c.1054A>G | p.Lys352Glu | p.K352E | Q9BW92 | protein_coding | tolerated(0.07) | possibly_damaging(0.543) | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| TARS2 | SNV | Missense_Mutation | c.2146G>A | p.Glu716Lys | p.E716K | Q9BW92 | protein_coding | deleterious(0.02) | benign(0.268) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| TARS2 | SNV | Missense_Mutation | novel | c.1555N>A | p.Leu519Met | p.L519M | Q9BW92 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |